As explained by the National Kidney Foundation, the goal of management of chronic hyperkalemia -- i.e., high levels of potassium in the blood -- is to prevent the development or recurrence of the ...

WILMINGTON, Del.--(BUSINESS WIRE)-- Today, the US Food and Drug Administration (FDA) approved a label update in the US for AstraZeneca’s LOKELMA® (sodium zirconium cyclosilicate) to include a dosing ...

—European investigators examined pretransplant plasma potassium levels and the need for potassium-lowering interventions to resolve hyperkalemia within 48 hours after kidney transplantation. Chronic ...